New York, NY (PRWEB) September 02, 2014
The use of Xarelto (known generically as rivaroxaban) and other new blood thinners is growing at a rapid pace, even as Xarelto lawsuits (http://www.xareltolawsuitcenter.com) continue to mount in courts around the U.S., Bernstein Liebhard LLP reports. According to a new study published in American Journal of Medicine, within a year of its 2011 launch, patients were just as likely to be prescribed Xarelto as warfarin, a blood thinner that has been in use for several decades. Commentary accompanying the study did note that there is currently no approved antidote for reversing internal bleeding that sometimes accompanies use of Xarelto and other new blood thinners, and advised that caution is required when the drugs are used in elderly patients or others at risk for this complications.*
“This study comes as a a growing Xarelto lawsuit plaintiffs claim to have been harmed by the blood thinner. The lack of a reversal agent for Xarelto bleeding noted in this study is one of the issues at the heart of these claims,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering Xarelto case reviews to people who allegedly suffered serious injuries from the blood thinner, including uncontrollable bleeding, strokes, deep vein thrombosis or pulmonary embolism.
Xarelto, which is jointly marketed by Bayer and Johnson & Johnson, belongs to a new class of anticoagulants known as direct thrombin inhibitors. Like any blood thinner, the medication can sometimes cause patients to experience internal hemorrhaging. However, no antidote has yet been approved for Xarelto bleeding. **
In recent months, a growing body of research has called the safety of Xarelto into question. For example, a report published in May by the Institute of Safe Medicine Practices revealed that the U.S. Food & Drug Administration had received a total of 680 Xarelto adverse event reports in the first quarter of 2013. For the first time, reports of complications associated with the medication outpaced those associated with Pradaxa, another blood thinner in the same class, according to the ISMP.***
In August, a study published in the Journal of Neurosurgery found that internal bleeding associated with Xarelto is more difficult to stop when compared to some other blood thinners. Among other things, the medication has a short half-life, requiring doctors to act more quickly to manage brain bleeds. The study also found that dialysis is not an effective way to reverse Xarelto bleeding. By contrast, bleeding from warfarin, an anticoagulant that has been used for decades, can be stopped via the administration of vitamin K.****
According to an earlier Reuters report, a growing number of Xarelto lawsuits have been filed in U.S. courts on behalf of patients who were allegedly injured by the drug.***** Court documents indicate that one of the most recent cases was filed in the U.S. District Court, Easter District of New York by the family of a Tennessee man who died due to a bleeding event allegedly caused by Xarelto. Among other things, the complaint alleges that Johnson & Johnson and Bayer failed to warn doctors and patients about the irreversible nature of Xarelto bleeding. It also claims that the companies wrongly touted the drug as a superior alternative to warfarin. (Case No. 2:14-cv-00159-cr)
Individuals who were allegedly harmed by Xarelto may be entitled to compensation for medical bills, lost wages, pain and suffering, and more. To learn more about filing a Xarelto lawsuit, please visit Bernstein Liebhard LLPs website, or call 800-511-5092 to schedule a free, no obligation case review.
*http://www.medscape.com/viewarticle/830315?src=rss, MedScape, August 23, 2014
**fda.gov/downloads/Drugs/DrugSafety/UCM280333.pdf, FDA, March 2014
***ismp.org/quarterwatch/pdfs/2013Q1.pdf, Institute for Safe Medication Practices, May 7, 2014.
****thejns.org/doi/pdf/10.3171/2014.8.paradigm, The Journal of Neurosurgery, August 1, 2014
*****reuters.com/article/2014/06/14/us-bayer-suit-idUSKBN0EP0HW20140614, Reuters.com, June 14, 2014.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
Read the full story at http://www.prweb.com/releases/xarelto-lawsuit/xarelto-bleeding/prweb12137613.htm.
Copyright©2014 Vocus, Inc.
All rights reserved